Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads by Date

Must reads for theWeek ending February 18, 2018

Mantle Cell Lymphoma Incidence Evaluated , Oncotarget; 2017 Nov; Fu, Wang, Lairson, et al

A Potential Marker for High-Grade Lymphoma , Clin Lymphoma Myeloma Leuk; ePub 2017 Dec 30; Shallis, et al

More must reads

Must reads for theWeek ending February 11, 2018

These Low-Grade NHLs Can Be Overlooked , Int J Surg Pathol; ePub 2018 Jan 1; Himchak, et al

This Protein Can Help Differentiate FL from MZL , Am J Surg Pathol; ePub 2018 Jan 5; Moore, et al

More must reads

Must reads for theWeek ending February 4, 2018

Ibrutinib in Relapsed/ Refractory FL Assessed , Blood; ePub 2018 Jan 11; Bartlett, et al

A Potential Biomarker for Ibrutinib Response? , Haematologica; 2017 Nov; Vos, Tsakmaklis, et al

More must reads

Must reads for theWeek ending January 28, 2018

Ibrutinib vs Chlorambucil in CLL/SLL Evaluated , Haematologica; ePub 2018 Jan 11; Coutre, et al

Obesity’s Impact on Elderly Patients with NHL, Blood; ePub 2017 Dec 7; Ip, Switchenko, et al

More must reads

Must reads for theWeek ending January 21, 2018

Strategies for Marginal Zone Lymphoma Reviewed, Future Oncol; ePub 2017 Dec 20; Rosand, et al

Improved QoL in SLL Seen When Ibrutinib Added , Leuk Lymphoma; ePub 2018 Jan 3; Cramer, et al

More must reads

Pages